-
Research Services<a class="dhimg1" href="/shichangdetail1/9.html" target="_self" rel="nofollow"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/8926ff01-64bc-4928-a995-396bdb9d8102.jpg" alt="Aniphe BioLab"> </a> <a class="dhimg2" href="/shichangdetail/8.html" target="_self" rel="nofollow"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/26342b34-4f1e-4d28-9166-7b685e6d70c3.jpg" alt="Aniphe BioLab"> </a>
-
-
Preclinical CRO<a class="dhimg1" href="/shichangdetail/6.html" target="_self" rel="nofollow"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/cc43bac1-07d9-4340-9677-fbe01c51330a.jpg" alt="Aniphe BioLab"> </a> <a class="dhimg2" href="/shichangdetail/10.html" rel="nofollow" target="_self"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/f1d8f739-0d36-4cb8-adeb-26de791d909c.jpg" alt="Aniphe BioLab"> </a>
-
-
-
-
Publish an article
Sepsis-associated ARDS
Introduction to Animal Models of Sepsis-Induced Lung Injury
The Ailinfei biological animal model of sepsis‑induced lung injury is constructed based on core pathogenic mechanisms, including dysregulated systemic inflammatory response, immune dysfunction, and disruption of pulmonary microvascular barrier function. It primarily induces systemic infection or endotoxin challenge to mimic the cascade of pulmonary inflammation, alveolar–capillary barrier damage, and pulmonary edema that occur in sepsis. This model accurately reflects the onset and progression of sepsis‑associated acute lung injury (ALI/ARDS).
Service Advantages of the Aniphe BioLablogical Sepsis-Induced Lung Injury Animal Model Platform
To provide a standardized, reproducible in vivo experimental model platform for studying the mechanisms of sepsis‑associated acute lung injury and for evaluating therapeutic efficacy.
![]() |
The model has been built to be mature and stable. The classic CLP (cecal ligation and puncture) model was employed, yielding a high success rate and robust phenotypic consistency. |
![]() |
The pathological phenotype is well-defined and controllable. It can reliably induce typical ALI/ARDS manifestations, including alveolar structural damage, inflammatory cell infiltration, and pulmonary edema. |
![]() |
Refinement of the multidimensional evaluation system The extent of injury was comprehensively assessed by integrating pulmonary histopathology, inflammatory cytokine measurements, and pulmonary function parameters. |
![]() |
Adaptable to diverse research needs Supports research on the mechanisms of acute inflammatory injury and the evaluation of pharmacological interventions across different time windows. |
![]() |
Complete data delivery specifications Provide raw experimental data, pathology slide images, and systematic analysis results to ensure data traceability and compliance with publication‑grade standards. |
|
The filament occlusion method (MCAO) is used to establish the model, which avoids craniotomy, minimizes animal trauma, and yields highly reproducible results. |
Standardized surgical protocols, combined with an experienced technical team, ensure the stability and consistency of model creation. |
The Longa score and the Bederson score, combined with TTC staining, were used to comprehensively validate the model’s phenotype. |
Retain photographs of key procedural milestones and original records to ensure traceability of the experimental process. |
A standardized in vivo solution that meets the needs of cerebral ischemia mechanism research and drug efficacy evaluation. |
| Modeling cycle | 1–2 weeks |
|
|
Mice and rats of SPF grade |
|
|
Common anti-inflammatory and lung-protective agents include dexamethasone, methylprednisolone, edaravone, and ulinastatin. |
|
|
It is widely used in studies of the mechanisms underlying sepsis‑associated acute lung injury, investigations into the regulatory networks of inflammatory cytokines, elucidation of the pathogenic mechanisms of pulmonary barrier dysfunction, and evaluation of the therapeutic efficacy of anti‑inflammatory and lung‑protective agents. |
Establishment of an Animal Model of Sepsis-Induced Lung Injury
01 After weighing the mice in a quiet environment, they were anesthetized. Once fully anesthetized, the abdominal fur was shaved, the mice were secured on the surgical table, and the exposed skin of the abdomen was disinfected with povidone‑iodine.
02 Maintain aseptic technique, and use a scalpel to sequentially incise the layers of tissue in the mouse’s abdomen until the abdominal cavity is opened; the surgical incision should be approximately 1 cm in length.
03 After locating the distal end of the mouse cecum, gently traction it into view, and ligate it with a sterile suture approximately 1 cm from the cecal tip. (If the distal end contains only a small amount of feces, use blunt forceps to gently compress the cecum, thereby extruding its contents toward the cecal terminus.)
04 Then, using a sterile 10-mL syringe needle, gently puncture the cecal ligation site twice, carefully express a small amount of feces and wipe the area clean, before returning the cecal stump to the mouse’s abdominal cavity.
05 After cleaning the wound, the mouse’s tissues were sequentially sutured layer by layer. Once the mouse had recovered from anesthesia, it was returned to its cage and maintained under stable housing conditions.
Model features: Cecal ligation and puncture in animals is the gold-standard model for reproducing clinical sepsis, particularly gastrointestinal perforation; it accurately reflects the bidirectional changes in immunology and hemodynamics that occur during the progression of sepsis.
Aniphe BioLab Inc.
Address:
Runcheng, No. 8 Longtai Road, Jiangbei New Area, Nanjing City, Jiangsu Province
Building 8, Science Park
Postal Code: 210007
Phone:025-8520 8061
Email:info@aniphebio.com(Consultation)
Email:order@aniphebio.com(Order)
WeChat Official Account
Video Account
















Positive drug
Application areas
Su Public Security Bureau Internet Information Service Filing No. 32010402001421